There is substantial variation in breast cancer survival rates, even among patients with similar clinical and genomic profiles. New biomarkers are needed to improve risk stratification and inform treatment options. The aim was to identify novel miRNAs associated with breast cancer survival, and quantify their prognostic value after adjusting for established clinical factors and genomic markers.